(Q37112871)

18 August 2017

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera (English)

1 reference

18 August 2017

15

Torsten Haferlach

1 reference

18 August 2017

2

Ulrike Bacher

1 reference

18 August 2017

3

Claudia Haferlach

1 reference

18 August 2017

1

Susanne Schnittger

1 reference

18 August 2017

Thomas Geer

4

1 reference

18 August 2017

Peter Müller

5

1 reference

18 August 2017

Johann Mittermüller

6

1 reference

18 August 2017

Petro Petrides

7

1 reference

18 August 2017

Rudolf Schlag

8

1 reference

18 August 2017

Reiner Sandner

9

1 reference

18 August 2017

Johannes Selbach

10

1 reference

18 August 2017

Hans Rainer Slawik

11

1 reference

18 August 2017

Hans Werner Tessen

12

1 reference

18 August 2017

Jürgen Wehmeyer

13

1 reference

18 August 2017

Wolfgang Kern

14

1 reference

18 August 2017

language of work or name

1 reference

1 March 2009

1 reference

18 August 2017

1 reference

18 August 2017

94

1 reference

18 August 2017

3

1 reference

18 August 2017

414-418

1 reference

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

JAK and MPL mutations in myeloid malignancies

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

JAK2 mutations and clinical practice in myeloproliferative neoplasms

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

JAK-2 mutations and their relevance to myeloproliferative disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

A gain-of-function mutation of JAK2 in myeloproliferative disorders

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649350

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19252176

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19252176

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19252176

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.13223

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

19252176

1 reference